HIV-1 entry - An expanding portal for drug discovery

Drug Discovery Today

Volumn 5, Issue 5, 2000, Pages 183-194

  Blair, Wade S ^a   Lin, Pin Fang ^a   Meanwell, Nicholas A ^a   Wallace, Owen B ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; NEW DRUG; RANTES;

ANTIVIRAL ACTIVITY; CELL INVASION; DRUG DELIVERY SYSTEM; DRUG RESEARCH; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; VIRUS LOAD;

EID: 0034194615     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01484-7     Document Type: Review

References (66)

1. Palella F.J.et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New Engl. J. Med. 338:1998;853-860.
2. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:1999;512-517.
3. Pomeranntz R.J. Primary HIV-1 resistance: a new phase in the epidemic? J. Am. Med. Assoc. 282:1999;1177-1179.
4. Siliciano R.F. Latency and reservoirs for HIV-1. AIDS. 13:1999;S49-S58.
5. Kilby J.M.et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1998;1302-1307.
6. Ugolini S.et al. HIV-1 attachment. another look Trends Microbiol. 7:1999;144-149.
7. Wyatt R.et al. The HIV-1 envelope glycoproteins. fusogens, antigens, and immunogens Science. 280:1998;1884-1888.
8. Chan D.C.et al. HIV entry and its inhibition. Cell. 93:1998;681-684.
9. Doms R.W.et al. Unwelcomed guests with master keys. how HIV uses chemokine receptors for cellular entry Virology. 235:1997;179-190.
10. Kwong P.D.et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
11. Wyatt R.et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-710.
12. Rizzuto C.D.et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280:1998;1949-1953.
13. Capon D.J.et al. The CD4-gp120 interaction and AIDS pathogenesis. Annu. Rev. Immunol. 9:1991;649-678.
14. Daar E.S.et al. Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. Am. J. Med. 90(Suppl. 4A):1991;22S-26S.
15. Moore J.P.et al. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66:1992;235-243.
16. Allaway G.P.et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses. 11:1995;533-539.
17. Gauduin M.-C.et al. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. J. Virol. 72:1998;3475-3478.
18. Ono M.et al. FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes. Nat. Biotechnol. 15:1997;343-348.
19. Zhang J.L.et al. The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry. Virology. 244:1998;530-541.
20. Ojwang J.O.et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39:1995;2426-2435.
21. Este J.A.et al. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 53:1998;340-345.
22. Wallace T.L.et al. Repeat-dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278:1996;1313-1317.
23. Rusconi S.et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40:1996;234-236.
24. Bourne N.et al. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J. Infect. Dis. 180:1999;203-205.
25. DeClercq E. Recent developments in the chemotherapy of HIV infections. Pure Appl. Chem. 70:1998;567-577.
26. Shaunak S.et al. Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS. AIDS. 12:1998;399-409.
27. - cells by two distinct mechanisms. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4867-4871.
28. Rosenstein I.J.et al. Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J. Infect. Dis. 177:1998;1386-1390.
29. Ross T.et al. Role of chemokine receptors in HIV-1 infection and pathogenesis. Adv. Virus Res. 52:1999;233-267.
30. Lapham C.K.et al. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science. 274:1996;602-605.
31. Trkola A.et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:1996;184-187.
32. Wu L.et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:1996;179-183.
33. Clapham P.R.et al. Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines. induction and enhancement by soluble CD4 J. Virol. 66:1992;3531-3537.
34. Hwang S.S.et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science. 253:1991;71-74.
35. Shioda T.et al. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 349:1991;167-169.
36. Hoffman T.L.et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6359-6364.
37. Connor R.I.et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:1997;621-628.
38. Liu R.et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:1996;367-377.
39. Zhang Y-J.et al. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type I entry? J. Virol. 73:1999;3443-3448.
40. Mosier D.E.et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73:1999;3544-3550.
41. Zou Y.-R.et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393:1998;595-599.
42. Nagasawa T.et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:1996;635-638.
43. + T cells. role of signal transduction Proc. Natl. Acad. Sci. U. S. A. 95:1998;11880-11885.
44. Cairns J.S.et al. Chemokines and HIV-1 second receptors. the therapeutic connection Nat. Med. 4:1998;563-568.
45. Tamamura H.et al. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochem. Biophys. Res. Commun. 189:1992;845-850.
46. Arakaki R.et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol. 73:1999;1719-1723.
47. Murakami T.et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186:1997;1389-1393.
48. Doranz B.J.et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186:1997;1395-1400.
49. Howard O.M.Z.et al. Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function. a candidate for chemotherapeutic and microbicidal application J. Med. Chem. 41:1998;2184-2193.
50. DeClercq E.et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38:1994;668-674.
51. Schols D.et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:1997;1383-1388.
52. Donzella G.A.et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:1998;72-77.
53. Labrosse B.et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AND3100. J. Virol. 72:1998;6381-6388.
54. Vereese K.D.et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70:1996;689-696.
55. Baba M.et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5698-5703.
56. Chan D.C.et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
57. Weissenhorn W.et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-430.
58. Tan K.et al. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 94:1997;12303-12308.
59. Wild C.T.et al. A synthetic peptide inhibitor of human immunodeficiency virus replication. correlation between solution structure and viral inhibition Proc. Natl. Acad. Sci. U. S. A. 89:1992;10537-10541.
60. Wild C.et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9770-9774.
61. Matthews T.J.et al. Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol. Rev. 1994;93-104.
62. Furata R.A.et al. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:1998;276-279.
63. Rimsky L.T.et al. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:1998;986-993.
64. Debnath A.K.et al. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42:1999;3203-3209.
65. Eckert D.M.et al. Inhibiting HIV-1 entry. discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket Cell. 99:1999;103-115.
66. Ferrer M.et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 6:1999;953-960.